David Block, CEO of Gliknik, to chair GBC Bioscience Committee

 

The Greater Baltimore Committee announced June 5 David S. Block, MD, president and CEO of Gliknik, Inc. has been named chair of the Greater Baltimore Committee’s Bioscience Committee. Dr. Block was chosen because of his leadership in the greater Baltimore bioscience community and his history of successful bioscience entrepreneurship.

“A key priority for this committee going forward will be supporting the creation and growth of innovative bioscience companies by ensuring access to capital,” Block said. “The committee intends to pursue this as its primary goal.”

An entrepreneur with more than 20 years in the biopharmaceutical industry, Block has also been an active advocate for the industry in the state legislature. He founded Gliknik, Inc. in 2007 after helping to found and develop Ruxton Pharmaceuticals, a venture capital-backed Johns Hopkins spinout focused on Lou Gehrig’s disease. Gliknik is a University of Maryland Baltimore spinout whose mission is to discover and develop new drugs for patients with autoimmune conditions and cancer.

Prior to becoming a small company entrepreneur, Block was the chief operating officer of Celera Genomics. Before Celera, he worked for 12 years at DuPont Merck where he served as the senior vice president of international operations.

Block received his MD from the University of Pennsylvania simultaneously with his M.B.A. from the Wharton School. He is board certified in internal medicine and HIV medicine, and has continuously cared for HIV patients for 20 years at the Johns Hopkins Moore Clinic in a voluntary capacity.

Block assumes the role of chair following Dr. Blake Paterson, CEO of Cerecor, Inc., who served five years in the position.

Comments are closed.